Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004311:Double-Blind Method; D017277:Drug Approval; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010919:Placebos; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D014481:United States; D014486:United States Food and Drug Administration
D010919:Placebos; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide